Tuesday, March 18, 2014

The Motley Fool: Is Intercept Pharmaceuticals, Inc. Overvalued?

With a $9 billion market cap and a stock that has shot up 1,167% over the past twelve months, it is not too surprising that expectations are high for Intercept Pharmaceuticals (NASDAQ: ICPT  ) and investors are nervous about even the slightest hint of trouble in the clinical pipeline. To that end, it would seem that investors are more nervous about the prospect of a cardiovascular safety issue in the Phase II study of lead compound obeticholic acid (or OCA) than cheered by another strong trial outcome in primary biliary cirrhosis.

Please read more here:
Is Intercept Pharmaceuticals, Inc. Overvalued?

No comments: